anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The awareness of the association between the gut microbiota and human intelligence levels is increasing, but the findings are inconsistent. Furthermore, few research have explored the potential role of gut microbial metabolites in this association. This study aimed to investigate the associations of the gut microbiota and fecal metabolome with intelligence quotient (IQ) in preschoolers.
METHODS: The 16 S rRNA sequencing and widely targeted metabolomics were applied to analyze the gut microbiota and fecal metabolites of 150 children aged 3-6 years. The Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition (WPPSI-IV) was used to assess the cognitive competence.
RESULTS: The observed species index, gut microbiome health index, and microbial dysbiosis index presented significant differences between children with full-scale IQ (FSIQ) below the borderline (G1) and those with average or above-average (all P < 0.05). The abundance of Acinetobacter, Blautia, Faecalibacterium, Prevotella_9, Subdoligranulum, Collinsella, Dialister, Holdemanella, and Methanobrevibacter was significantly associated with preschooler's WPPSI-IV scores (P < 0.05). In all, 87 differential metabolites were identified, mainly including amino acid and its metabolites, fatty acyl, and benzene and substituted derivatives. The differential fecal metabolites carnitine C20:1-OH, 4-hydroxydebrisoquine, pantothenol, creatine, N,N-bis(2-hydroxyethyl) dodecanamide, FFA(20:5), zerumbone, (R)-(-)-2-phenylpropionic acid, M-toluene acetic acid, trans-cinnamaldehyde, isonicotinic acid, val-arg, traumatin, and 3-methyl-4-hydroxybenzaldehyde were significantly associated with the preschooler's WPPSI-IV scores (P < 0.05). The combination of Acinetobacter, Isonicotinic acid, and 3-methyl-4-hydroxybenzaldehydenine may demonstrate increased discriminatory power for preschoolers in G1.
CONCLUSION: This study reveals a potential association between gut microbiome and metabolites with IQ in preschoolers, providing new directions for future research and practical applications. However, due to limitations such as the small sample size, unclear causality, and the complexity of metabolites, more validation studies are still needed to further elucidate the mechanisms and stability of these associations.
PURPOSE:A drug for external use, containing nojirimycin or a sulfurous acid adduct thereof and having excellent inhibitory action on melanin and whitening and beautifying action as well as high safety. CONSTITUTION:A drug for external use obtained by blending nojirimycin expressed by the formula (R is OH or SO2OH) or a sulfurous acid adduct in various bases for external use and formulated into the form of ointment, gel, pack or cosmetic, e.g. cream, foundation, etc. The amount of the nojirimycin blended in the drug for external use is preferably 1-20wt%. The effect of the compound expressed by the formula is entirely different from that of conventional whitening and beautifying agents and based on the conversion of the saccharide chain of tyrosinase and inhibition of development of tyrosinase activity. The whitening and beautifying effect of the compound expressed by the formula is remarkable with high safety.
The electrode pads of the transcutaneous electrical nerve stimulation (TENS 7000) will be placed at the base of the penis (and perineum). Participants will be able to use the device prior to sexual activity (immediately before sexual encounter for 10 minutes or daily for up to 14 days prior) to "prime" their system or during sexual activity. Each participant will use the device these three separate ways for 6 weeks each (total of 18 weeks of use).
Marijuana contains many chemicals called cannabinoids. The ingredient mainly responsible for marijuana's psychoactive effects is called THC (delta-9-tetrahydrocannabinol. Another cannabinoid in marijuana is cannabidiol. It is found in smaller quantities than THC. Cannabidiol is thought to interfere with the effects of THC. Therefore, synthetically produced cannabidiol is given to healthy marijuana users in this study to test its capability to reduce the high of THC and, thereby, help to relieve addiction to marijuana.
The aim of the work was to study a dose-dependent effect of inhaled carnosine (10, 50 or 100 mg/kg/day) in mice exposed to cigarette smoke as a model of chronic obstructive pulmonary disease (COPD). A dose-dependent loading of the dipeptide in lung tissue and bronchoalveolar lavage (BAL) was firstly demonstrated by LC-ESI-MS analysis. Cigarette smoke exposure induced a significant lung inflammation and oxidative stress in mice which was dose-dependently reduced by carnosine. Inflammation was firstly evaluated by measuring the cytokines content in the BAL. All the measured cytokines were found significantly higher in the smoke group in respect to control, although the data are affected by a significant variability. Carnosine was found effective only at the highest dose tested and significantly only for keratinocyte-derived cytokine (KC). Due to the high variability of cytokines, a quantitative proteomic approach to better understand the functional effect of carnosine and its molecular mechanisms was used. Proteomic data clearly indicate that smoke exposure had a great impact on lung tissue with 692 proteins differentially expressed above a threshold of 1.5-fold. Protein network analysis identified the activation of some pathways characteristic of COPD, including inflammatory response, fibrosis, induction of immune system by infiltration and migration of leukocyte pathways, altered pathway of calcium metabolism and oxidative stress. Carnosine at the tested dose of 100 mg/kg was found effective in reverting all the pathways evoked by smoke. Only a partial reverse of the dysregulated proteins was evident at low- and mid-tested doses, although, for some specific proteins, indicating an overall dose-dependent effect. Regarding the molecular mechanisms involved, we found that carnosine upregulated some key enzymes related to Nrf2 activation and in particular glutathione peroxidase, reductase, transferase, SOD, thioredoxins, and carbonyl reductase. Such mechanism would explain the antioxidant and anti-inflammatory effects of the dipeptide.
The invention relates to a piece of patchouli essential oil handmade soap for removing comedos and acnes and a fabrication method thereof. The patchouli essential oil handmade soap is prepared from the following raw materials: patchouli essential oil, olive oil, sodium palmate, flaked soap, glycerinum, coconut oil, shea butter, castor oil and deionized water according to certain weight ratio. The fabrication method comprises the following steps: (1) mixing the olive oil, the sodium palmate, the flaked soap, the glycerinum, the coconut oil, the shea butter, the castor oil and the deionized water according to the ratio; heating until the mixture is completely dissolved, stirring and cooling the mixture to 50-55 DEG C; (2) adding patchouli essential oil to the mixed oil and evenly stirring; (3) pouring into a die for solidifying; (4) demolding and packaging to obtain the product. The patchouli essential oil handmade soap can be used for cleaning the skin of the overall body, and has the effects of removing comedos and acnes, sterilizing, diminishing inflammation, cooling down, moisturizing, supplying water, nourishing the skin, and whitening spots. The flavor of pogostemon cablin can be used for soothing feeling, relieving pressure and removing anxiety. The patchouli essential oil handmade soap adopts pure natural plant juice, is free of stimulation to skin, and is an environmental bath product which can be used for a long period of time.
1. Technical Result Increase of medicinal preparation stability.   2. Essence A composition contains ibuprofen or a pharmaceutically acceptable salt thereof, effervescent system containing alkaline carbonate and organic acid and pharmaceutically acceptable antioxidant. A pharmaceutical preparation contains said composition associated with pharmaceutical adjuvant substance. For obtaining of a preparation the effervescent system is prepared by mixing of alkaline carbonate and organic acid, the pharmaceutical adjuvant substance is introduced therein and the obtained mixture is added with ibuprofen treated with antioxidant or one of its salts.    3. Field of Application Medicine, therapy.
NEW MATERIAL:Human pancreatic trypsin III having the amino acid sequence of formula I. USE:Similar to trypsin extracted and purified from human pancreatic juice, the titled trypsin is useful for the improvement of symptoms such as abscess, ulcer, scald, bed sore, gangrene, ecchymoma, contaminated wound, difficulty in expectoration accompanying to respiratory diseases, etc. PREPARATION:A cDNA bank is prepared by using mRNA separated from human pancreas and a reverse transcriptase. One clone having a DNA coding the objective novel human pancreatic trypsinogen III is obtained from the bank by colony hybridization using swine pancreatic trypsinogen cDNA, etc., as a probe. A PstI fragment of said clone is subcloned to a cloning vector pSV2 to obtain the objective DNA. The objective trypsin, etc., can be produced from a transformation prepared by introducing said DNA into a host.
PCT No. PCT/AU96/00370 Sec. 371 Date Dec. 19, 1997 Sec. 102(e) Date Dec. 19, 1997 PCT Filed Jun. 20, 1996 PCT Pub. No. WO97/00693 PCT Pub. Date Jan. 9, 1997A pharmaceutical or veterinary formulation comprising deslorelin and an excipient is provided which releases in vitro deslorelin into phosphate buffered saline at 370 DEG  C. at a rate of about 2-80  mu g/day for at least 200 days. The formulation may be used for prevention of reproductive function, particularly in dogs and cats, and for the treatment particularly in humans, of prostate and breast cancer and other diseases and conditions where suppression of testosterone or estradiol levels is beneficial.
A method, system and product for medication adherence management. The method comprises obtaining data about a user, wherein the data comprises a prescription of a medication to be administered to the user. A user context data is calculated for the user. An intervention and timing thereof are determined for the user based on the user context. The determination may be performed using a prediction model that is trained with respect to a cohort, wherein the user is a member of the cohort. The intervention is implemented on the user at the determining timing of the intervention.
Controlled release insect repellent or insecticide based on a non-aqueous gel composition comprising from about 1 to about 20 weight percent of one or more diblock, triblock, radial block and/or multiblock copolymers, or a mixture thereof, based on synthetic thermoplastic rubbers. The ratio of the diblock copolymer to triblock, radial block and/or multiblock copolymer can be varied from about 0 percent to about 100 percent in either direction. The higher the tri-block percentage, the stiffer the resultant gel. The material to be gelled is a hydrocarbon which based on its physical properties plays an important role in setting the controlled release rate. The composition of the hydrocarbon can vary in carbon chain length from an average of about C-13 to about C-30 and can vary in vapor pressure from about 2.3 mm Hg at 20 DEG  C. to less than about 0.1 mm Hg at 20 DEG  C. The hydrocarbon range on a weight basis is from about 65 to about 95 percent of the total weight of the gelled composition. The controlled release agent or active agent may comprise from about 0.1 to about 30 percent of the gel on a weight basis.
The invention discloses an extract with blood-sugar reducing activity extracted from a Dai medicine Clerodendranthus spicatus (Thunb.) C.Y. WuexH. W. Li, a preparation method of the extract, a medicinal composition containing the Clerodendranthusspicatus (Thunb.) C.Y. WuexH. W. Li extract, as well as application of the Clerodendranthusspicatus (Thunb.) C.Y. WuexH. W. Li extract and a medicinal composition thereof in preparing medicaments and health-care products, in particular medicaments and health-care products for treating and preventing metabolic diseases related to diabetes mellitus, complications and the like thereof.
NSAIDs, including nabumetone, can cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. NSAIDs can also cause fixed drug eruption (FDE). FDE may present as a more severe variant known as generalized bullous fixed drug eruption (GBFDE), which can be life-threatening. These serious events may occur without warning. Inform patients about the signs and symptoms of serious skin reactions, and to discontinue the use of nabumetone tablets at the first appearance of skin rash or any other sign of hypersensitivity. Nabumetone tablets are contraindicated in patients with previous serious skin reactions to NSAIDs (see CONTRAINDICATIONS).
Childhood eye cancers, although rare, present substantial health challenges, affecting the pediatric population with a remarkable impact on their lives and families. This comprehensive review provides insights into the various types of ocular tumors, primarily focusing on malignant eye tumors, their genetic predispositions, and advancements in managing these conditions. Understanding the genetic risk factors is crucial for early detection, risk assessment, and the development of targeted therapies. This review discusses genome-wide association (GWAS) and next-generation sequencing (NGS) studies to find common and rare genetic variants. Furthermore, it also explores the outcomes and implications of these genetic discoveries in treating pediatric ocular cancer. These findings underscore the significance of genetic research in guiding early interventions and improving outcomes in children with ocular cancers.
Comparison group will not receive any intravenous treatment. Both experimental and comparison groups will receive an oral iron supplementation (100 mg/day).
The invention relates to an insomnia-curing herb-filled pillow. With continuous increase of living level and continuous quickening of living tempo, more and more people are troubled by insomnia. Insomnia brings poor rest and great inconvenience for the work on the next day. Especially for people often working at night, poor sleep quality due to daytime quarrel, strong sunlight and the like is a big issue to be solved. Present insomnia medicines in market are expensive and are easy to cause dependency to a patient in long-term use. The insomnia medicines seem to be beneficial to sleep but actually damage the health of the patient.
The RP2D/OBD of JK06 determined by the Escalation arm. A cycle of treatment is defined as 21 days.
BNT141 was planned to be administered Q3W. Nab-paclitaxel and gemcitabine was planned to be administered on three days of each 28-day cycle.
Isolation and characterization of human umbilical cord-derived mesenchymal stem cells (UCMSCs): Human umbilical cord tissues along with informed consent forms will be collected from hepatitis B, C, and COVID-19 virus-negative women with healthy pregnancies during the Cesarean Section surgery after completion of gestation period. The cord tissue will be transported in sterile 1x phosphate-buffered saline (PBS) containing 200 units/ml penicillin and 200 µg/ml streptomycin on ice. In the biosafety cabinet, the cord will be washed with 4-5 changes of sterile 1x PBS and placed in a Petri plate with 15 ml PBS. The cord will be gently scraped with a surgical blade to remove any dead cells. A 9 cm umbilical cord will be cut into three equal pieces and wash thoroughly to remove blood clots, umbilical cord arteries, and veins. Segments will be washed three times with PBS and minced. The minced pieces will be incubated in 17.5 ml of collagenase solution (201 U/ml collagenase type I in serum-free DMEM-HG) in a 50 ml conical tube for \~3.5 hours in an incubator at 5% CO2, 95% humidity at 37⁰C. After \~3.5 hours, the digested lysate will pass through a strainer and will be diluted three times with 1x PBS. Following centrifugation, the cells will be seeded into two 25 cm2 flasks and will be placed in an incubator at 5% CO2, 95% humidity at 37⁰C. The flasks will be fed with fresh media (DMEM-HG supplemented with 20% FBS and 1% antibiotic solution) every third day. At around day 18, cells will reach up to 85% confluency and will be transferred in two 75 cm2 flasks with media replaced at alternate days. UCMSCs at P3 will be characterized using different specific antibodies. Cells at P3 will be used for transplantation in patients. Fifteen (15) subjects will be treated with three intravenous infusions (IV) of 500,000 UCMSCs per Kg body weight delivered via peripheral intravenous infusion.
Delayed cerebral vasospasm is a major complication following subarachnoid hemorrhage and a primary cause of delayed cerebral ischemia. While various preventive treatments exist, some patients still develop severe vasospasm, highlighting the need for better rescue therapies. This article explores endovascular treatment as a rescue option for vasospasm, focusing on the clinical characteristics and roles of intra-arterial vasodilator injection therapy and percutaneous transluminal angioplasty(PTA). Despite a lack of strong evidence from large clinical trials, advancements in endovascular technology have positioned both intra-arterial vasodilator injection therapy and PTA as promising and safe rescue options for severe vasospasm. Careful selection of the appropriate approach is crucial for achieving optimal clinical outcomes, considering the unique characteristics, advantages, and limitations of each method. Further clinical trials are necessary to definitively confirm this hypothesis.
Participants will engage in 16 sessions of somatic yoga and meditation with appropriate props as needed over 8 weeks and continue with a home practice. Application of SYM throughout activities of daily living is reinforced. All sessions are facilitated by trained yoga therapists.
The participants in the control group will receive daily text-messages to prompt their reporting of CAT-scores. To avoid attrition of the trial due to early recovery of symptoms, the project manager will call the participants by phone at day 15 to ask them about their present condition (i.e. CAT-score) and address potential concerns of continued participation of the trial. Otherwise, they will only receive usual care.
PURPOSE: A cosmetic composition of retinoid low irritation is provided to protect skin from retinoid irritation and inflammation. CONSTITUTION: A cosmetic composition contains retinoid and a material which reversibly suppresses retinal dihydronase. The material is citral and is contained in 0.01-0.5 wt% based on total weight. The citral includes cis and trans. The composition is used for anti-aging, anti-wrinkling, and retinoid relief. The cosmetic composition is manufactured in the form of a skin softener, massage cream, nutrition cream, pack, gel, lotion, ointment, or spray.
A novel Coronavirus (SARS-CoV-2) described in late 2019 in Wuhan, China, has led to a pandemic and to a specific coronavirus-related disease (COVID-19), which is mainly characterized by a respiratory involvement. While researching for a vaccine has been started, effective therapeutic solutions are urgently needed to face this threaten. The renin-angiotensin system (RAS) has a relevant role in COVID-19, as the virus will enter host's cells via the angiotensin-converting enzyme 2 (ACE2); RAS disequilibrium might also play a key role in the modulation of the inflammatory response that characterizes the lung involvement. Angiotensin-(1-7) is a peptide that could be altered in COVID-19 patient and it may potentially improve respiratory function in this setting. This a randomized, controlled, investigator-initiated Phase I/Phase II trial is conceived to test the safety and the efficacy of intravenous angiotensin-(1-7) infusion in COVID-19 patients with severe pneumonia admitted to the intensive care unit (ICU). The first phase of the study, with a limited number of patients (n=30) will serve to confirm the safety of the intravenous infusion of the drug by observing the incidence of the adverse events (phase I, open label). In a second phase of the study, conducted in a double-blind manner and including a larger cohort of patients (n=100, Phase II), patients will be randomly assigned to receive either an Angiotensin-(1-7) infusion or placebo. The primary endpoint of the study will be the number of supplemental oxygen-free days by day 28. Secondary outcomes will include length of hospital stay, ICU and hospital free days, ICU and hospital mortality, need for mechanical ventilation, weaning time from mechanical ventilation if intubated, secondary infections, vasopressor needs, changes in PaO2 / FiO2, incidence of deep vein thrombosis, changes in inflammatory markers, plasma levels of angiotensin II and angiotensin (1-7) and radiological findings.
Two multicenter, randomized, double-blind studies were conducted. In Study One, 1,407 subjects were randomized to one of four treatment groups: Taclonex Scalp® Topical Suspension, betamethasone dipropionate in the same vehicle, calcipotriene hydrate in the same vehicle, or the vehicle alone. Study Two did not include a vehicle arm; 1,280 subjects were randomized to one of three treatment groups: Taclonex Scalp® Topical Suspension, betamethasone dipropionate in the same vehicle, or calcipotriene hydrate in the same vehicle. Both studies enrolled subjects with moderate to very severe scalp psoriasis. The majority of subjects had disease of moderate severity at baseline. Subjects were treated once daily for 8 weeks.

Efficacy was assessed as the proportion of patients at Week 8 with absent or very mild disease according to an Investigator’s Global Assessment of Disease Severity. "Clear" was defined as no evidence of redness, thickness or scaling. "Almost clear" was defined as an overall clinical picture of lesions with the presence of minimal erythema. Table 2 contains the response rates in each of these two trials.
A healthy diet prevents overweight problems and hypertension. We investigated the associations of a healthy diet with the body mass index (BMI) and blood pressure (BP) in early childhood. In the GECKO birth cohort, height, weight, and BP were measured at 5 and 10 years of age. Diet was evaluated at 3 years using three diet scores: the Dietary Approaches to Stop Hypertension (DASH), the Mediterranean Diet Score (MDS), and the Lifelines Diet Score (LLDS). Linear and logistic regression models assessed the associations of diet scores with the BMI and BP. Of the 1077 children included, 10.8% were overweight or obese at 5 years. That number was 16.5% at 10 years. In addition, 34.5% had elevated BP at 5 years. That number was 23.9% at 10 years. Higher DASH, MDS, and LLDS, which indicate healthier diets, were all associated with lower BMI z-scores at 10 years of age. Higher DASH is related to lower overweight risk at 10 years. None of the diet scores were associated with BP or elevated BP at either 5 or 10 years. Also, in an overweight subset, diet was not related to BP. A healthy diet in early childhood is related to children being less overweight but not having lower BP at 10 years of age.
The participants will engage in a total of four weeks of intervention. The intervention sessions are conducted three times per week, there will be a total of 12 intervention sessions. The participants in control group will watch a language enhancement video.